As of January 22, 2025, Cabaletta Bio (CABA) has a market cap of $0.12 billion USD. According to our data, Cabaletta Bio is ranked No.7526 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.12 B |
11.89%
|
Dec 31, 2024 | $0.11 B |
-90.00%
|
Dec 29, 2023 | $1.11 B |
145.41%
|
Dec 30, 2022 | $0.45 B |
144.06%
|
Dec 31, 2021 | $0.19 B |
-69.63%
|
Dec 31, 2020 | $0.61 B |
-10.67%
|
Dec 31, 2019 | $0.68 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Autolus Therapeutics
AUTL
|
$0.57 B |
0.000 M
|
UK
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Market Cap | = | CABA Stock Price | * | CABA Shares Outstanding |
= | $2.54 | * | 48.88 M | |
= | $0.12 B |